慢性髓性白血病HLA配体组图谱界定用于免疫治疗的新型T细胞表位
本研究采用质谱法在慢性髓性白血病(CML)原代样本中鉴定自然呈递的HLA I类和II类限制性肽,通过与多种血液良性标本及深度分子学缓解CML样本的配体组比较,界定出一组新型频繁呈递的CML专属肽,并证实其可诱导自发性T细胞反应及多功能细胞毒性T细胞。
要点
- 质谱法鉴定CML原代样本中自然呈递的HLA I类和II类限制性肽
- 比较配体组界定出新型频繁呈递的CML专属肽
- 新肽可在CML患者中引发自发性T细胞反应并诱导健康志愿者和CML患者样本中多功能细胞毒性T细胞
核心结论
- 这些抗原是T细胞免疫治疗的主要候选靶点,可能延长无TKI生存期甚至介导CML治愈。
研究设计与样本
- 研究采用基于质谱的方法,在CML原代样本中鉴定自然呈递的HLA I类和II类限制性肽。
- 比较HLA配体组分析使用了不同血液良性标本和深度分子学缓解CML患者样本的综合数据集。
主要发现
- 比较配体组分析界定出一组新型频繁呈递的CML专属肽。
- 这些非突变靶抗原尤其相关,因为广泛的数据挖掘提示缺乏自然呈递的BCR-ABL和ABL-BCR来源的HLA限制性肽,且已知癌/睾丸抗原和白血病相关抗原缺乏频繁的肿瘤专属呈递。
- 功能表征显示CML患者样本中存在针对新鉴定CML相关肽的自发性T细胞反应。
- 这些肽能够在健康志愿者和CML患者样本中从头诱导多功能和细胞毒性抗原特异性T细胞。
临床怎么用
- 作者认为这些抗原是T细胞免疫治疗的主要候选靶点,可能延长无TKI生存期甚至介导CML治愈。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antileukemia immunity plays an important role in disease control and maintenance of tyrosine kinase inhibitor (TKI)-free remission in chronic myeloid leukemia (CML). Thus, antigen-specific immunotherapy holds promise for strengthening immune control in CML but requires the identification of CML-associated targets. In this study, we used a mass spectrometry-based approach to identify naturally presented HLA class I- and class II-restricted peptides in primary CML samples. Comparative HLA ligandome profiling using a comprehensive dataset of different hematological benign specimens and samples from CML patients in deep molecular remission delineated a panel of novel frequently presented CML-exclusive peptides. These nonmutated target antigens are of particular relevance because our extensive data-mining approach suggests the absence of naturally presented BCR-ABL- and ABL-BCR-derived HLA-restricted peptides and the lack of frequent tumor-exclusive presentation of known cancer/testis and leukemia-associated antigens. Functional characterization revealed spontaneous T-cell responses against the newly identified CML-associated peptides in CML patient samples and their ability to induce multifunctional and cytotoxic antigen-specific T cells de novo in samples from healthy volunteers and CML patients. Thus, these antigens are prime candidates for T-cell-based immunotherapeutic approaches that may prolong TKI-free survival and even mediate cure of CML patients.
引用
- Bilich T, Nelde A, Bichmann L, et al. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood. 2018. PMID: 30530751. doi:10.1182/blood-2018-07-866830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。